IDH2 and central nervous system cancer: Regarding to the development molecular based glioma classification, WHO CNS5 (WHO2021) has therefore included molecular diagnostic criteria such as IDH mutation CDKN2A/B homozygous deletion for the classification of infiltrating gliomas.